Format

Send to

Choose Destination
Oncotarget. 2017 Mar 21;8(12):19760-19767. doi: 10.18632/oncotarget.15035.

Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients.

Author information

1
Cancer Center Key Laboratory, Chinese PLA General Hospital & Chinese PLA Medical School, Beijing 100853, P. R. China.
2
Molecular Pathology Laboratory, College of Basic Medicine, Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China.
3
Department of General Surgery, The First Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China.
4
Department of Endocrine, Chinese PLA 309 Hospital, Beijing 100071, P. R. China.
5
Department of Pathology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia 010059, P. R. China.
6
International Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, P. R. China.

Abstract

OBJECTIVE:

Previous studies have suggested a correlation between glucose transporter-1 (GLUT-1) expression and survival outcomes in pancreatic cancer, although the results were inconsistent. We subsequently carried out a meta-analysis, with the aim of comprehensively reevaluating the associations between GLUT-1 expression and overall survival (OS) and other clinical features of pancreatic cancer.

RESULTS:

Eight studies, with a total of 538 cases, were included in the final meta-analysis. The HR and 95% CI for OS were 1.79 and 1.19-2.7, respectively (p=0.005). GLUT-1 overexpression was associated with tumor size (>2 cm vs. ≤2 cm; OR=2.16, 95% CI=1.2-3.9, p=0.01) and lymph node metastasis (yes vs. no; OR=3.29, 95% CI=1.38-7.84, p=0.007). However, there was no significant association between GLUT-1 expression and histological grade, age, sex, TNM stage, or vascular invasion status. There was no evidence of significant publication bias in this meta-analysis.

MATERIALS AND METHODS:

Relevant databases were searched using predefined searching items until September 2016. The pooled hazard ratios (HR) with 95% confidence interval (CI) for OS and the pooled odds ratio (OR) with 95% CI for clinical factors were calculated.

CONCLUSIONS:

High GLUT-1 expression predicted shorter OS in patients with pancreatic cancer. Moreover, GLUT-1 expression was associated with a tumor size of >2 cm and presence of lymph node metastasis.

KEYWORDS:

biomarker; clinical; epidemiology; meta-analysis; pancreatic cancer

PMID:
28178665
PMCID:
PMC5386719
DOI:
10.18632/oncotarget.15035
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center